Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00619775 · ClinicalTrials.gov registry record · Phase 3

Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial

A Phase 3 study of Carotid Artery Disease, sponsored by Medtronic Endovascular.

Completed
Registry status
Phase 3
Development phase
419
Enrollment target
20
Study locations

NCT00619775: Completed Phase 3 study of Carotid Artery Disease, sponsored by Medtronic Endovascular.

NCT00619775 is a Phase 3 study of Carotid Artery Disease that has completed, run by Medtronic Endovascular. The registered enrollment target is 419 participants, below the 13,649-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00619775, a Phase 3 study of Carotid Artery Disease, has completed, sponsored by Medtronic Endovascular.

COMPLETED
Registry status
Phase 3
Development phase
419 participants
Enrollment target
20
Study locations

Study Summary

Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.

Conditions Studied

Interventions

  • DEVICE PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device

Study Locations (20)

California

  • Scripps Memorial Hospital - La Jolla
  • El Camino Hospital - Mountain View
  • Hoag Memorial Hospital - Newport Beach
  • Salinas Valley Memorial Healthcare System - Salinas

Indiana

  • St. Vincent Hospital & Health Care Centers - Indianapolis
  • The Heart Center of Indiana - Indianapolis

Louisiana

  • Terrebonne General Hospital - Houma
  • Southwest Medical Center - Lafayette

Maryland

  • Union Memorial Hospital - Baltimore
  • Washington Adventist Hospital - Takoma Park

Michigan

  • Oakwood Hospital - Dearborn
  • William Beaumont Hospital - Royal Oak

North Carolina

  • Duke University Medical Center - Raleigh
  • Wake Heart Associates - Raleigh

Arizona

  • Banner Baywood Heart Hospital - Mesa

District of Columbia

  • Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 419 participants
Start Date 2004-04
Est. Completion 2005-10
Phase Phase 3
Medtronic Endovascular

25 total trials

What the finished NCT00619775 record still lists

NCT00619775 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, below the 13,649-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Carotid Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device is the first listed.

NCT00619775 names 20 study sites across 12 states, led by California, Indiana, Louisiana.

Frequently Asked Questions

What is clinical trial NCT00619775 about?

NCT00619775 is a clinical study titled "Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial". Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.

What is the current status of trial NCT00619775?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2004-04. Estimated completion is 2005-10.

What conditions does trial NCT00619775 study?

This clinical trial studies the following conditions: Carotid Artery Disease.

What interventions are being tested in trial NCT00619775?

The interventions under investigation include: PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device (DEVICE).

Who is sponsoring clinical trial NCT00619775?

This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00619775 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Carotid Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05579639 · 419 participants · Phase 2

    Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

  • NCT01790152 · 420 participants

    Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • NCT02701244 · 420 participants

    A Registry Study of Breast Microseed Treatment

  • NCT02966665 · 420 participants · Phase 1

    : Vascular Function in Health and Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00619775, the US trial registry maintained by the National Library of Medicine. NCT00619775 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.